Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in th
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2010 Phytomedics, Inc., a transformational healthcare company ... products solely derived from plant sources, announced today ... the amount of $244,000 under the Qualifying Therapeutic ... of its lead product PMI-001 for Rheumatoid Arthritis. ...
... Nov. 9, 2010 NewCardio, Inc. (OTC Bulletin Board: ... announced today that Dr. Samuel George, NewCardio,s Senior Medical ... a blinded "testing" dataset, conducted independently by the Cardiac ... to be held on December 9, 2010, at the ...
Cached Medicine Technology:Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Model Compliance Guidance , , ... Compliance Association (HCCA) announced today that it will hold ... in Scottsdale, Arizona. The HCCA,s Managed Care Compliance conference, ... to provide essential information for individuals involved with managing ...
... Calif., Dec. 4 Microchip Biotechnologies, a private company ... announced today that Ezra Van Gelder has joined its ... , Ezra Van Gelder brings ... development from the life science, medical device and semiconductor ...
... LAKE CITY, Dec. 4 The Ensign Group, Inc.,(Nasdaq: ... Ensign(TM) group of skilled nursing,rehabilitative care services and assisted ... of Infinia at Alta, an 85-bed skilled,nursing facility in ... Alta,Care & Rehabilitation Center. , ...
... can become,stressful for many families -- the pressure to find ... and co-workers, and, this,year, the added weight of a slumping ... give the gift of companionship and joy by putting a ... "Before giving a furry friend as a gift, ...
... Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that ... proteins*, are quantitatively related to the mortality rate in human cancer ... been reported to be quantitatively related to mortality rate. , ... ...
... Wash., Dec. 4 In the midst of ... challenges in the United States,healthcare providers from across ... corporate headquarters in Redmond, Wash., for the first ... examining,ways to apply information technology (IT) innovations to ...
Cached Medicine News:Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 2Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 3Health News:Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D 2Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:A Season of Responsibility for New Pet Owners 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4
... lathing techniques, intrinsically permeable polymers and advanced ... thickness of just 0.08 across all minus ... lenses maintain a 30% decrease in center ... eliminates stress points to reduce the chance ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... developed to stain intraocular membranes in vitreoretinal ... By injecting Membraneblue in an air-filled vitreous ... diluting the dye. After removal of all ... membranes can easily be distinguished from the ...
Medicine Products: